1. FDA: FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed November 15, 2011
2. Tonelli MKS Wiebe N Shrive F Hemmelgarn B Manns B : Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation. Technology Report Number 106, Ottawa, Canada, Canadian Agency for Drugs and Technologies in Health, 2008
3. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study.;Bahlmann;Contrib Nephrol,1991
4. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
5. Trends in anemia treatment with erythropoietin usage and patient outcomes.;Collins;Am J Kidney Dis,1998